Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Cd73 Is An Immunometabolic Biomarker Of Poor Prognosis In Patients With Primary Cutaneous Squamous Cell Carcinoma And Hematologic Malignancy.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Cd73 Is An Immunometabolic Biomarker Of Poor Prognosis In Patients With Primary Cutaneous Squamous Cell Carcinoma And Hematologic Malignancy.

Related Experiment Video

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and Hematologic Malignancy.

Vahide Saeidi1, Stephanie R Jackson Cullison, Nicole A Doudican

  • 1All authors are affiliated with the Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.

Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|July 8, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

CD73 is highly expressed in cutaneous squamous cell carcinoma (cSCC) in patients with hematologic malignancy, indicating it may be a biomarker for poor prognosis and a potential therapeutic target.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

Related Experiment Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Impaired immunity contributes to cutaneous squamous cell carcinoma (cSCC) aggressiveness in hematologic malignancy patients.
  • Precise mechanisms and prognostic biomarkers for cSCC in this population are not well-defined.
  • CD73 elevates immunosuppressive adenosine, linked to poor prognosis in various tumors.

Purpose of the Study:

  • To identify biomarkers associated with poor outcomes in patients with cSCC and hematologic malignancy.

Main Methods:

  • NanoString analysis identified differentially expressed genes in tumors from patients with good versus poor outcomes.
  • CD73 protein levels were validated using immunohistochemistry in cSCC patients with and without hematologic malignancy.

Main Results:

  • Forty-eight genes showed differential expression between good and poor outcome groups.
  • CD73 gene expression was significantly higher in poor outcome patients and normal skin.
  • Elevated CD73 protein levels were observed in cSCC tumors with poor prognosis in hematologic malignancy patients (p < .01), but not in those without hematologic malignancy (p = .49).

Conclusions:

  • CD73 is highly expressed in poor-prognosis cSCC within the hematologic malignancy cohort.
  • CD73 may serve as a valuable prognostic biomarker.
  • CD73 presents a potential therapeutic target for cSCC in patients with hematologic malignancy.